Discovery of a Novel Dual-Targeting KRASG12D/HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer - PubMed
5 hours ago
- #Pancreatic Cancer
- #KRASG12D
- #HDAC Inhibitor
- Discovery of KH-1, a novel peptide inhibitor targeting both KRASG12D and HDAC for pancreatic cancer treatment.
- KH-1 shows nanomolar binding affinity for KRASG12D (Kd = 11.63 ± 0.71 nM) and HDAC2 (Kd = 20.17 ± 1.26 nM).
- Significant inhibition of pancreatic cancer cell proliferation, invasion, and migration by KH-1.
- KH-1 induces apoptosis and cell cycle arrest at the G0/G1 phase in pancreatic cancer cells.
- Demonstrated tumor growth inhibition in xenograft models without significant organ toxicity.